The stock of Haemonetics Corporation (NYSE:HAE) is a huge mover today! About 485,903 shares traded hands or 39.05% up from the average. Haemonetics Corporation (NYSE:HAE) has declined 0.03% since April 5, 2016 and is downtrending. It has underperformed by 1.99% the S&P500.
The move comes after 8 months positive chart setup for the $1.88B company. It was reported on Nov, 7 by Barchart.com. We have $55.14 PT which if reached, will make NYSE:HAE worth $940.00M more.
Haemonetics Corporation (NYSE:HAE) Ratings Coverage
Out of 7 analysts covering Haemonetics Corporation (NYSE:HAE), 2 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 29% are positive. Haemonetics Corporation has been the topic of 11 analyst reports since July 29, 2015 according to StockzIntelligence Inc. On Monday, November 23 the stock rating was downgraded by Raymond James to “Underperform”. The rating was maintained by Barrington Research on Tuesday, October 6 with “Outperform”. The firm has “Hold” rating given on Thursday, November 5 by Benchmark. Benchmark maintained Haemonetics Corporation (NYSE:HAE) on Wednesday, May 11 with “Hold” rating. The company was upgraded on Tuesday, July 28 by Barrington Research. Jefferies maintained it with “Buy” rating and $40 target price in Tuesday, August 2 report. On Tuesday, September 20 the stock rating was downgraded by CJS Securities to “Market Perform”. The firm has “Neutral” rating given on Monday, May 16 by Goldman Sachs. On Monday, August 15 the stock rating was downgraded by Sidoti to “Neutral”.
According to Zacks Investment Research, “Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections and plasma collections. The majority of their business is outside the US.”
Insitutional Activity: The institutional sentiment decreased to 1.55 in 2016 Q2. Its down 0.20, from 1.75 in 2016Q1. The ratio worsened, as 18 funds sold all Haemonetics Corporation shares owned while 44 reduced positions. 31 funds bought stakes while 65 increased positions. They now own 50.62 million shares or 0.12% more from 50.56 million shares in 2016Q1.
Menta Limited Liability holds 0.18% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 45,900 shares. Federated Pa holds 1,886 shares or 0% of its portfolio. Martingale Asset L P has invested 0.03% of its portfolio in Haemonetics Corporation (NYSE:HAE). Goldman Sachs Grp Incorporated holds 0% or 232,483 shares in its portfolio. Tfs Capital Ltd Co last reported 35,457 shares in the company. Jacobs Levy Equity owns 16,550 shares or 0.01% of their US portfolio. State Street has 1.02M shares for 0% of their US portfolio. Fuller And Thaler Asset Management holds 1.06% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 2.13M shares. The Tennessee-based First Mercantile Trust Company has invested 0.05% in Haemonetics Corporation (NYSE:HAE). Morgan Stanley has invested 0% of its portfolio in Haemonetics Corporation (NYSE:HAE). Marshall Wace Limited Liability Partnership owns 25,949 shares or 0.01% of their US portfolio. Moreover, Numeric Investors Llc has 0.01% invested in Haemonetics Corporation (NYSE:HAE) for 52,900 shares. Blackrock Institutional Na has invested 0.01% of its portfolio in Haemonetics Corporation (NYSE:HAE). Parametric Port Associates Limited Liability Company accumulated 183,826 shares or 0.01% of the stock. Sei Com last reported 2,701 shares in the company.
Insider Transactions: Since August 4, 2016, the stock had 1 buying transaction, and 2 insider sales for $1.43 million net activity. On Wednesday, August 17 the insider MERRIMAN RONALD sold $152,398. On Friday, August 5 the insider FOOTE SUSAN BARTLETT sold $519,105. Simon – Christopher bought $2.10M worth of stock.
More news for Haemonetics Corporation (NYSE:HAE) were recently published by: Prnewswire.com, which released: “Haemonetics Corporation Announces Christopher Simon as President and Chief …” on May 09, 2016. Prnewswire.com‘s article titled: “Haemonetics Corporation Appoints Ron Gelbman as Interim CEO; CEO Brian …” and published on September 29, 2015 is yet another important article.
HAE Company Profile
Haemonetics Corporation (Haemonetics), incorporated on August 29, 1985, is a healthcare company. The Firm provides various products to clients involved in the processing, handling and analysis of blood. The Company’s divisions include Japan, EMEA, North America Plasma and All Other. It provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. It provides analytical devices for measuring hemostasis, which enable healthcare providers to manage their patients’ bleeding risk. Haemonetics makes blood processing systems, and software, which tracks blood components. Haemonetics supplies systems and software, which facilitate blood transfusions and cell processing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.